Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
about
Autoantibodies against neuropeptides are associated with psychological traits in eating disordersFrom ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use?Disruption of the vasopressin 1b receptor gene impairs the attack component of aggressive behavior in miceVasopressin: behavioral roles of an "original" neuropeptideGenetic, epigenetic and environmental impact on sex differences in social behavior.The vasopressin 1b receptor is prominent in the hippocampal area CA2 where it is unaffected by restraint stress or adrenalectomyPharmacological treatment of anxiety disorders: current treatments and future directionsInnovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?Individual differences in gene expression of vasopressin, D2 receptor, POMC and orexin: vulnerability to relapse to heroin-seeking in ratsThe Vasopressin 1b Receptor Antagonist A-988315 Blocks Stress Effects on the Retrieval of Object-Recognition Memory.Chronic mild stress (CMS) in mice: of anhedonia, 'anomalous anxiolysis' and activityCurrent investigational drugs for major depressionChronic Treatment with the IDO1 Inhibitor 1-Methyl-D-Tryptophan Minimizes the Behavioural and Biochemical Abnormalities Induced by Unpredictable Chronic Mild Stress in Mice - Comparison with FluoxetineNeuroanatomical evidence for reciprocal regulation of the corticotrophin-releasing factor and oxytocin systems in the hypothalamus and the bed nucleus of the stria terminalis of the rat: Implications for balancing stress and affectViral vector-mediated gene transfer of the vole V1a vasopressin receptor in the rat septum: improved social discrimination and active social behaviourAlterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressinA Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence.Mouse models of fear-related disorders: Cell-type-specific manipulations in amygdala.Social isolation and chronic handling alter endocannabinoid signaling and behavioral reactivity to context in adult ratsThe vasopressin Avpr1b receptor: molecular and pharmacological studies.The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsReduced ultrasonic vocalizations in vasopressin 1b knockout mice.Sex differences in response to chronic mild stress and congenital serotonin deficiencyLearning and memory impairments in a neuroendocrine mouse model of anxiety/depressionA hypomorphic vasopressin allele prevents anxiety-related behavior.A complex selection signature at the human AVPR1B geneDrug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases.Depression shows divergent effects on evoked and spontaneous pain behaviors in rats.Open questions in current models of antidepressant action.Hypericum perforatum treatment: effect on behaviour and neurogenesis in a chronic stress model in mice.Social dominance in male vasopressin 1b receptor knockout mice.Vasopressin modulates medial prefrontal cortex-amygdala circuitry during emotion processing in humans.Evaluation of anxiolytic activity of the essential oil of the aerial part of Foeniculum vulgare Miller in miceInteraction of stress, corticotropin-releasing factor, arginine vasopressin and behaviour.The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in ratsNeuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice.Anxiolytic-like effects of mitragynine in the open-field and elevated plus-maze tests in rats.Vasopressin inhibits LTP in the CA2 mouse hippocampal area.SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.
P2860
Q24534812-A2E6ADD2-9C93-441B-BE7A-90BF0004F966Q24648383-3C2CC020-D9A1-4265-990B-0DB506A05438Q24654065-9BFF3A29-0CDC-4F7E-B36D-25EDEE523BB7Q24656284-60FF6A4E-8E69-4EC3-9C65-AEF12F3C67DFQ24657105-24774D85-3E03-4E96-95E3-A92644EDD348Q24676940-7FE03519-2C7A-443D-AAEB-CE089E5383A2Q26851461-68B4D396-1838-4EC4-B7A2-5F7EFABBA18DQ26996411-7A8C6686-86AD-4906-A60C-9744D7A4BA22Q27304542-A7D9ED61-A262-4E39-A0A4-36BE353D9D9FQ27310716-3826EE23-F2B2-4CE8-86F5-61377A796697Q27438109-A157F716-5EC6-4AEC-9436-EABDB722CD84Q28244223-B253CD01-18EA-4F90-BBF2-1C01F36AFA54Q28553299-475A81DE-AD84-40E7-BD66-890E98D9FF00Q28565572-6E890D90-E394-49D7-9A99-F81274C6330DQ28573042-5F4DF591-0578-4A3E-98B0-3F1B50B8F1BEQ28576962-53B0C678-9171-4177-867A-26B81313788DQ30275691-E9F8601C-2B30-48F5-9773-28067F1ADC5FQ30357301-6B9DBF88-17F3-4111-A6B3-A1C0F043AC61Q30475004-A2F68CC4-139A-4A03-993C-ECBD4DAEDC2FQ30477659-3DE0417C-C5CB-4244-8E36-6DC310C78624Q30486707-3E7F3583-6123-4084-A933-F8A413145674Q30490834-D5EA0A41-CFC4-438E-A8FE-B7EC0936A2B5Q30571260-516C4308-2EE7-4E9D-956D-854C1CD3456CQ30577635-1BAF64CB-CE74-4F14-A6C3-531A08A48C3DQ33428525-77D353D3-A2F5-4213-B729-0F1C0308BEF1Q33457712-99CEFC34-34E8-4660-A1F5-8938935F1009Q33643136-F37B4E5C-4DBC-4313-AAAF-F42A02E2DAA6Q33716636-5A3BAA63-3CFE-43C6-8E37-F8B8C884F8B3Q33767182-C3BAD824-5843-4454-89A7-C4552D0942F3Q33805327-A9AFA895-3600-472B-B414-336B437D97A2Q33888987-A8740A31-622C-4E44-80CA-1F709580A6E6Q33891814-99CBBC1B-1F25-4D39-A426-46AAF8447B1DQ34143912-990044F3-5B1C-466E-8323-F0B549BAF7BAQ34225879-AC7CDED7-459F-4474-B0C4-FDA5D81BA1DDQ34226624-30C14031-F8B0-4E6A-8DF3-8009F35C240CQ34275762-3F9561DF-A426-4CE8-993F-45DD940967C1Q34292427-1C364762-46A3-44C6-B9AA-33B84B551ED2Q34400172-5AF08F51-C45B-4FE5-8ECA-3322B52AADEFQ34510263-01C5204D-E82A-4915-BAAE-7CDFAD092248Q34561031-1EE6153C-5A40-466C-8269-079D319C7ED6
P2860
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Anxiolytic- and antidepressant ...... nt of stress-related disorders
@nl
Anxiolytic- and antidepressant ...... t of stress-related disorders.
@ast
Anxiolytic- and antidepressant ...... t of stress-related disorders.
@en
type
label
Anxiolytic- and antidepressant ...... nt of stress-related disorders
@nl
Anxiolytic- and antidepressant ...... t of stress-related disorders.
@ast
Anxiolytic- and antidepressant ...... t of stress-related disorders.
@en
prefLabel
Anxiolytic- and antidepressant ...... nt of stress-related disorders
@nl
Anxiolytic- and antidepressant ...... t of stress-related disorders.
@ast
Anxiolytic- and antidepressant ...... t of stress-related disorders.
@en
P2093
P2860
P3181
P356
P1476
Anxiolytic- and antidepressant ...... nt of stress-related disorders
@en
P2093
Bernard Scatton
Claudine Serradeil-Le Gal
Jacques Simiand
Jean Wagnon
Jean-Pierre Maffrand
Marc Pascal
Philippe Soubrie
P2860
P304
P3181
P356
10.1073/PNAS.092012099
P407
P50
P577
2002-04-16T00:00:00Z